The Signal
Google search interest for "GastroPlus," Simulations Plus's flagship absorption modeling software, hit a normalized score of 60 on April 4, 2026, up 71% from 35 in early January and 22% above the same week one year ago. Search volume reached 9,818 estimated weekly queries, compared to 8,018 a year prior. The keyword "Simulations Plus" itself is up 88% year-over-year and 39% over the past three months in search interest. These are not brand-awareness spikes — GastroPlus is a software tool used by pharmaceutical scientists. When search interest rises, it typically reflects active evaluation or use.
What It Shows
The baseline for GastroPlus search was stable between 2024 and mid-2025, running in the 40–55 normalized range. The 3-month acceleration to 60 is a change in state, not continued elevation of an already-elevated trend. It coincides directly with a period of announced strategic expansion: on March 26, 2026, Simulations Plus disclosed three separate collaboration programs with large pharmaceutical companies to embed its AI agents into model-informed drug development (MIDD) workflows across GastroPlus, MonolixSuite, ADMET Predictor, and Thales. Those collaboration programs are not just pilots — management described them as defining "future commercial models" and involving enterprise IT governance for AI deployment.
Consensus entering fiscal Q2 2026 earnings (reported tonight after market close) estimates revenue of $21.7 million, which would be a 3.5% year-over-year decline from the $22.4 million Simulations Plus reported in fiscal Q2 2025. The prior quarter, Q1 fiscal 2026, came in at $18.4 million in revenue, beating estimates while missing EPS. The sequential comparison implies $21.7 million requires roughly 18% quarter-over-quarter growth — steep, but consistent with Simulations Plus's seasonal pattern of stronger H2 in its fiscal year (August year-end).
The market's consensus "Hold" rating with a $25 price target implies the stock at $13.00 is pricing in limited confidence in the revenue guidance reaffirmation. Fiscal year 2026 guidance is $79–82 million in total revenue.
The Company Link
Simulations Plus (Nasdaq: SLP) sells biosimulation software and related consulting services to pharmaceutical, biotech, and regulatory agencies. The License and Maintenance segment represents 58% of revenue; the Services segment makes up the remaining 42%. Software licenses are the higher-margin segment and are where new AI collaboration deals are most likely to register. The GastroPlus platform dominates absorption, distribution, metabolism, and excretion simulation — a category mandated by the FDA and increasingly required for drug submissions globally.
A structural tailwind exists that makes the timing notable: the FDA has been increasingly encouraging "in silico" methods to reduce the cost and timeline of drug development, creating a regulatory pull on adoption that is independent of pharmaceutical R&D budget cycles.
What to Watch
Tonight's earnings call should be monitored for any update on the three March 2026 AI collaboration programs and whether they are translating into recognized revenue or backlog. Management commentary on the Services pipeline matters more than any single quarterly number — the collaboration model implies recurring, structured engagements rather than one-time license sales. A revenue result above $21.7 million combined with reaffirmation of the $79–82 million full-year guidance would validate the demand signal. A miss combined with unchanged guidance would still leave the year intact but narrow the range. Guidance reduction would be the falsifying signal for this thesis.
This is for informational purposes only and does not constitute investment advice.
